approval
saveRINVOQ (UPADACITINIB) — FDA approval
community read0 votes
Sponsor: ABBVIE. Form: TABLET, EXTENDED RELEASE. Route: ORAL
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- approvalRINVOQ (UPADACITINIB) — FDA approvalOct 10, 2025 · 359d ago
- approvalRINVOQ (UPADACITINIB) — FDA approvalApr 28, 2025 · 524d ago
- approvalRINVOQ (UPADACITINIB) — FDA approvalMar 26, 2025 · 557d ago
- approvalRINVOQ (UPADACITINIB) — FDA approvalApr 26, 2024 · 891d ago
- approvalRINVOQ (UPADACITINIB) — FDA approvalApr 26, 2024 · 891d ago
- approvalRINVOQ (UPADACITINIB) — FDA approvalNov 14, 2023 · 1055d ago
- approvalRINVOQ (UPADACITINIB) — FDA approvalJun 22, 2023 · 1200d ago
- approvalRINVOQ (UPADACITINIB) — FDA approvalMay 18, 2023 · 1235d ago
same company · ±60 days · 6
- approvalrisankizumab: SKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalSep 3, 2025
- approvalrisankizumab: SKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalSep 3, 2025
- approvaladalimumab: HUMIRA (ADALIMUMAB) — FDA approvalJul 16, 2025
- approvalatogepant: QULIPTA (ATOGEPANT) — FDA approvalSep 30, 2025
- approvalESCITALOPRAM OXALATE — FDA approvalOct 9, 2025
- approvalupadacitinib tartrate ER: RINVOQ (UPADACITINIB) — FDA approvalOct 10, 2025
comments(0)
5-min edit window · permanent after that